参草通脉颗粒对慢性心衰的药效学及作用机制研究  

Pharmacodynamic and Mechanism Study of Shencaotongmai Granule in Treating Chronic Heart Failure

作　　者：王懿[1] 张艳[1] 

机构地区：[1]辽宁中医药大学,辽宁沈阳110847

出　　处：《辽宁中医杂志》2015年第4期879-882,共4页Liaoning Journal of Traditional Chinese Medicine

基　　金：沈阳市科技计划项目(11158)

摘　　要：目的:探讨中药复方参草通脉颗粒对慢性心衰模型大鼠的药效作用几作用机制。方法:SD大鼠复制成急性心肌缺血模型,以左室射血分数EF值≤60%为指标筛选心衰模型。心衰成膜大鼠随机分为模型组、中药中剂量组、中药大剂量组、西药组,除模型组及空白组外,给药组连续给药6周后处死大鼠,并取血清及心脏组织。采用Elisa法检测血清中血管紧张素Ⅱ(AngⅡ)、血浆肾素(PRA)、纤溶酶原激活物抑制物-Ⅰ(PAI-Ⅰ)的表达。采用免疫组化法检测心肌组织中AngⅡ和PKC的表达。应用PCR法检测心脏组织中AT1 mRNA的表达。结果:与模型组相比,各给药组大鼠血清中AngⅡ、PRA、PAI-Ⅰ及心脏组织中PKC、AT1 mRNA的表达量均不同程度的降低,其中中药中剂量组作用效果最好,接近空白组。结论:参草通脉颗粒对慢性心衰具有良好的治疗作用,其作用机制可能与下调AT1-mRNA表达,从而抑制了PRA、AngⅡ的表达,抑制RAS系统的异常激活,降低PKC的生成,从而减缓心肌重塑,阻滞心肌肥厚,降低血栓形成等有关。Objective：Study on traditional Chinese medicine（TCM） compound effects and mechanism of shencao tongmai granules on rats with chronic heart failure.Methods：Copy SD rats as acute myocardial ischemia model.Make them hungry and swim to run them out for 4 weeks.Divide heart failure rats into model group,dose TCM group（5.4 g / kg·d）,high dose TCM group（16.2 g / kg·d）,and Western medicine（Families 4.5mg / kg·d）.Continuously drug for 6 weeks and set up blank control group.Test content of angiotensinⅡ（AngⅡ） and protein kinase c（PKC）,plasminogen activator inhibitor-I（PAI-I） when stop the drug.Results：Compared with model group,contents of serum Ang II,PKC and PAI-I rats in all above groups decrease with some different degree.Conclusion：Shencao tongmai granules have treatment effect on chronic heart failure.The mechanism may relate to Inhibition of the RAS system activation,Reduce Ang II of myocardial tissue,inhibit mediated myocardial hypertrophy of PKC activity of a kind of signal molecule,the synthesis and release of PAI-I of reducing endothelial cells.

关 键 词：参草通脉颗粒 慢性心衰 药效学 作用机制 

分 类 号：R541[医药卫生—心血管疾病]